

---

# Applications For Amendment On 27 June 2012

Matching for 'Applications for Amendment' during June  
2012.

**IPMonitor**  
Patents

---

# Contents

Alerts .....	3
1 event .....	3
Terms and Conditions .....	4
General .....	4
Disclaimer of warranty and limitation of liability .....	4
Copyright .....	4
Arbitration .....	4

# Alerts

## 1 event

17 results matching for 'Applications for Amendment' during June 2012.

Number	Title	Date
<a href="#">2005278962</a>	Isoindolin-1-one derivatives	27 Jun 2012
<a href="#">2005285243</a>	Process for concentration of antibodies and therapeutic products thereof	27 Jun 2012
<a href="#">2006210513</a>	Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions	27 Jun 2012
<a href="#">2006304205</a>	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response	27 Jun 2012
<a href="#">2007214689</a>	Method for improving dog food	27 Jun 2012
<a href="#">2007255197</a>	Document automation systems	27 Jun 2012
<a href="#">2007257680</a>	Hydrophilized substrate and method for hydrophilizing a hydrophobic surface of a substrate	27 Jun 2012
<a href="#">2007266307</a>	Multi-gene expression vehicle	27 Jun 2012
<a href="#">2007306384</a>	Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers	27 Jun 2012
<a href="#">2008267167</a>	Kallikrein 7 modulators	27 Jun 2012
<a href="#">2008271051</a>	Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders	27 Jun 2012
<a href="#">2008276140</a>	Anti-CD79b antibodies and immunoconjugates and methods of use	27 Jun 2012
<a href="#">2008329673</a>	Novel compounds and compositions and methods of use	27 Jun 2012
<a href="#">2009202178</a>	Method for descaling a metal strip	27 Jun 2012
<a href="#">2009208100</a>	Decorative perforated facing for acoustic panels	27 Jun 2012
<a href="#">2010206058</a>	Succinate and malonate salt of trans4-(1R,3S)-6-chloro-3-Phenylindan-1-yl)- 1,2,2-trimethylpiperazine and their use as a medicament	27 Jun 2012
<a href="#">2011203119</a>	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics	27 Jun 2012

---

# Terms and Conditions

## General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

## Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

## Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

## Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at [www.IPMonitor.com.au/trademarks/info/terms](http://www.IPMonitor.com.au/trademarks/info/terms)